FRLN News and Press, Freeline Therapeutics Holdings plc From 11/29/22

LONDON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that it received approval from the Nasdaq Stock Market LLC (“Nasdaq”) to transfer the listing of its Americ...

Freeline Therapeutics press release ( NASDAQ: FRLN ): 9M GAAP EPS of -$1.15. Unrestricted cash and cash equivalents were $65.8 million as of September 30, 2022, compared to $117.7 million as of December 31, 2021. With the changes announced today, Freeline now expects that ...

Entered into definitive agreement to sell CMC-focused German subsidiary and related IP for $25 million, while retaining rights to AAVS3 capsid and maintaining access to capabilities and technologies Streamlining organization and extending cash runway into 2024 Prioritizi...

LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stifel Healthcare Conference being held in New York. The fireside chat will take place on No...

LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on October 31, 2022, the Company granted three newly hired employees non-statutory options to purchase an aggregate of 75,500 of the Company’s ordinary shares. The...

LONDON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on September 30, 2022, the Company granted five newly hired employees non-statutory options to purchase an aggregate of 416,850 of the Company’s ordinary shares. T...

LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1 clinical trial of FLT190 in Fabry disease, a debilitating inherited disorder that leads t...

LONDON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on August 31, 2022, the Company granted two newly hired employees non-statutory options to purchase an aggregate of 64,050 of the Company’s ordinary shares. ...

Summary Shares have fallen by 30% so far in 2022. Durability and safety for the Fabry disease gene therapy program continues to look best-in-class and enrollment should accelerate due to investigator enthusiasm. Excitement is palpable for CAR-Treg programs as renal transplant ...

Freeline Therapeutics press release ( NASDAQ: FRLN ): Q2 GAAP EPS of -$0.95 misses by $0.44 . Unrestricted cash and cash equivalents were $90.0 million as of June 30, 2022, as compared to $117.7 million as of year-end 2021. Freeline expects that its current level of ca...